Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
Research output: Contribution to journal › Journal article › Communication
Standard
Glucagon-like peptide-1 : from extract to agent. The Claude Bernard Lecture, 2005. / Holst, Jens Juul.
In: Diabetologia, Vol. 49, No. 2, 02.2006, p. 253-60.Research output: Contribution to journal › Journal article › Communication
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucagon-like peptide-1
T2 - from extract to agent. The Claude Bernard Lecture, 2005
AU - Holst, Jens Juul
PY - 2006/2
Y1 - 2006/2
N2 - The incretin hormones are intestinal polypeptides that enhance postprandial insulin secretion. Gastric inhibitory polypeptide (GIP) was initially thought to regulate gastric acid secretion, whereas glucagon-like peptide-1 (GLP-1) was discovered as a result of a systematic search for intestinal insulinotropic products of proglucagon gene expression. The incretin effect is markedly impaired or absent in patients with type 2 diabetes because of decreased secretion of GLP-1 and a loss of the insulinotropic effects of GIP. Metabolic control can be restored or greatly improved by administration of exogenous GLP-1, but this peptide is almost immediately degraded by dipeptidyl peptidase IV (DPP-IV), and therefore has little clinical value. DPP-IV-resistant analogues (incretin mimetics) have been identified or developed, and inhibitors of DPP-IV have also proved effective in protecting endogenous GLP-1 (and GIP) from degradation. Both principles have been tested in clinical studies. The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA(1)c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years. The DPP-IV inhibitors, given once or twice daily by mouth, also appear to provide lasting improvement in HbA(1)c, but are weight-neutral. The first incretin mimetic has reached the market in the US, and applications for approval of the first inhibitors are expected to be filed early in 2006.
AB - The incretin hormones are intestinal polypeptides that enhance postprandial insulin secretion. Gastric inhibitory polypeptide (GIP) was initially thought to regulate gastric acid secretion, whereas glucagon-like peptide-1 (GLP-1) was discovered as a result of a systematic search for intestinal insulinotropic products of proglucagon gene expression. The incretin effect is markedly impaired or absent in patients with type 2 diabetes because of decreased secretion of GLP-1 and a loss of the insulinotropic effects of GIP. Metabolic control can be restored or greatly improved by administration of exogenous GLP-1, but this peptide is almost immediately degraded by dipeptidyl peptidase IV (DPP-IV), and therefore has little clinical value. DPP-IV-resistant analogues (incretin mimetics) have been identified or developed, and inhibitors of DPP-IV have also proved effective in protecting endogenous GLP-1 (and GIP) from degradation. Both principles have been tested in clinical studies. The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA(1)c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years. The DPP-IV inhibitors, given once or twice daily by mouth, also appear to provide lasting improvement in HbA(1)c, but are weight-neutral. The first incretin mimetic has reached the market in the US, and applications for approval of the first inhibitors are expected to be filed early in 2006.
KW - Blood Glucose
KW - Diabetes Mellitus, Type 2
KW - Dipeptidyl Peptidase 4
KW - Gastric Inhibitory Polypeptide
KW - Glucagon-Like Peptide 1
KW - Hemoglobin A, Glycosylated
KW - Humans
KW - Hypoglycemic Agents
KW - Injections, Subcutaneous
KW - Insulin
KW - Intestines
KW - Peptides
KW - Protease Inhibitors
KW - Receptors, Glucagon
KW - Venoms
U2 - 10.1007/s00125-005-0107-1
DO - 10.1007/s00125-005-0107-1
M3 - Journal article
C2 - 16416146
VL - 49
SP - 253
EP - 260
JO - Diabetologia
JF - Diabetologia
SN - 0012-186X
IS - 2
ER -
ID: 132052980